Day One Biopharmaceuticals (DAWN)
US Market

Day One Biopharmaceuticals Cash flow


Day One Biopharmaceuticals Cash Flow

DAWN's free cash flow for Q3 2022 was $-23.22M. For the 2022 fiscal year, DAWN's free cash flow was decreased by $-42.96M and operating cash flow was $-23.21M. See a summary of the company’s cash flow.
Cash Flow
Dec 21Dec 20Dec 19
Operating Cash Flow
$ -87.73M$ -48.54M$ -13.49M$ -4.51M
Investing Cash Flow
$ -252.86M$ -8.00M$ -92.00K$ 0.00
Financing Cash Flow
$ 164.30M$ 297.12M$ 29.98M$ 30.91M
Cash Flow From Discontinued Operation
Other Cash Adjustment Inside Changein Cash
End Cash Position
$ 1.06B$ 284.31M$ 43.73M$ 27.33M
Income Tax Paid Supplemental Data
Interest Paid Supplemental Data
Issuance Of Capital Stock
$ 161.93M$ 296.80M$ 29.98M$ 29.91M
Issuance Of Debt
-$ 0.00$ 0.00$ 1.00M
Repayment Of Debt
Free Cash Flow
$ -87.76M$ -56.54M$ -13.58M$ -4.51M
Domestic Sales
Foreign Sales
Currency in USD

Day One Biopharmaceuticals Cash Flow

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis